Older patients, TP53 mutation fusion or MLL rearranged, which are independent adverse prognostic factors for AML patients (2), had higher risk scores, and those with RUNX1-RUNX1T1, a favorable fusion gene, had lower risk scores. The gene discussed is KMT2A; the disease is acute myeloid leukemia.